Home
Conditions
Lymphatic Diseases

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

9,002 public trials 1,838 recruiting studies

Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Active, not recruiting

Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

NCT06189183

Conditions: Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +3 more
Locations: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing, Beijing Municipality, China

View Trial Details

Active, not recruiting

Risk Factors, Incidence, and Progression of Lymphedema Among Men With Prostate Cancer. The AWARE Cohort

NCT07607431

Conditions: Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +12 more
Locations: Rigshospitalet Copenhagen, Denmark

Herlev and Gentofte Hospital Herlev, Denmark

Zealand University Hospital Roskilde, Denmark

View Trial Details

Active, not recruiting

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

NCT02427451

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, not recruiting

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

NCT01430390

Conditions: Acute Lymphocytic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations: Memorial Sloan Kettering Cancer Center New York, United States

View Trial Details

Active, not recruiting

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

NCT04439292

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

NCT04324112

Conditions: Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Active, not recruiting

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

NCT05673785

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations: Beijing Cancer Hospital Beijing, China

Peking University Third Hospital Beijing, China

The First Hospital of Jilin University Changchun, China

West China Hospital, Sichuan University Chengdu, China

View all 16 locations

View Trial Details

Active, not recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

NCT04505254

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

NCT04960618

Conditions: Advanced Mycosis Fungoides, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States

View Trial Details

Active, not recruiting

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

NCT04566887

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: BC Cancer Agency Vancouver, British Columbia, Canada

QEII Health Sciences Centre Halifax, Nova Scotia, Canada

Princess Margaret Cancer Centre Toronto, Ontario, Canada

Sunnybrook Research Institute Toronto, Ontario, Canada

View Trial Details

Lymphatic Diseases

Lymphatic Diseases trial results

Related conditions